nsaids 1 st line of therapy in the medical management of ra
TRANSCRIPT
![Page 1: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/1.jpg)
NSAIDs
1st line of therapy in the medical management of RA
![Page 2: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/2.jpg)
• Control the symptoms and signs of local inflammatory process
• Minimal effect on the progression of the disease
• i.e. Diclofenac sodium, naproxen sodium, etc.
![Page 3: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/3.jpg)
• COX-2 inhibitors– Suppresses COX that is involved in inflammation– Less damaging to the stomach– Associated with increased risk of cardiovascular
events
![Page 4: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/4.jpg)
GLUCOCORTICOIDS
2nd line of therapy
![Page 5: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/5.jpg)
• Systemic GC therapy– Provide effective symptomatic therapy in patients
with RA– Low dose PREDNISONE (<7.5 mg/dl)
• Useful additive therapy to control symptoms• May retard the progression of bone erosions• Initial course of low dose GC may have a long term
protective effect against bone damage • LOW DOSE GC + DMARD therapy (i.e. Methotrexate) can
be beneficial in controlling sins and symptoms rapidly and affording long term retardation of bone erosion
Source: Harrison’s Principles of Internal Medicine 17th ed.
![Page 6: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/6.jpg)
DMARDS(Disease-Modifying Anti-rheumatic Drugs)
3rd line of therapy
![Page 7: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/7.jpg)
• Slows down the progression of joint destruction
• Slow acting because it may take 6 weeks to 6 months for it to become evident
• Methotrexate, azathioprine, penicillamine, hydroxychloroquine and chloroquine, organic gold compounds, sulfasalazine
![Page 8: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/8.jpg)
Methotrexate
• DMARD of FIRST choice to treat RA• Individuals with RF for development of bone
erosions or persistent synovitis or >3months
![Page 9: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/9.jpg)
• MOA:– Inhibition of aminoimidazolecarboxamide
ribonucleotide (AICAR) transformylase and thymidylate synthetase, with secondary effects on polymorphonuclear chemotaxis
![Page 10: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/10.jpg)
• Pharmacokinetics– 70% absorbed after oral administration– Metabolized to a less active hydroxylated
metabolite and both the parent compound and the metabolite are polyglutamated within cells where they stay for prolonged periods
– Half-life: 6-9 hours– Increased in the presence of hydroxychloroquine– Excreted primarily in the urine
![Page 11: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/11.jpg)
• Indications– Dosing regimen: 15-25 mg weekly, 30 or 35 mg
weekly has an increased effect– Decreases the rate of appearance of new erosions– Juvenile chronic arthritis, ankylosing spondylitis,
polymyositis, dermatomyositis, Wegener’s granulomatosis, giant cell arteritis, SLE and vasculitis
• Maximal improvement is observed after 6 months of therapy
![Page 12: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/12.jpg)
• Adverse Effects– Nausea and mucosal ulcers – most common– GI upset– Progressive dose-related hepatotoxicity (enzyme
elevation) occurs frequently– Contraindicated in pregnancy
Source: Basic and Clinical Pharmacology 10th edition, 2007 by Katzung
![Page 13: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/13.jpg)
BIOLOGICS
4th line of therapy
![Page 14: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/14.jpg)
• Slows down progression of damage to articular structures
• Major impact on the signs and symptoms of RA
![Page 15: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/15.jpg)
• TNG-neutralizing agents– Infliximab, etanercept and adalimumab
• IL-1 neutralizing agents– Anakinra
• B-cell inhibitors– Rituximab
• Inhibition of T cell activation– Abatacept
![Page 16: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/16.jpg)
ABATACEPT
![Page 17: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/17.jpg)
• MOA:– Costimulation modulator that inhibits the
activation of T cells.
![Page 18: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/18.jpg)
• Pharmacokinetics– IV infusion – 3 doses (day 0, week 2 and week 4) initially– Followed by monthly infusions– Dose is based on body weight
• <60kg – 500mg• 60-100kg – 750mg• >100kg – 1000g
– Half-life: 13-16 days– Coadministration with methotrexate, NSAIDs and
corticosteroids does not influence clearance of abatacept
![Page 19: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/19.jpg)
• Indications– Can be used as monotherapy or in combination
with other DMARDs in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to DMARDs or TNF antagonists.
– Reduces the clinical signs and symptoms of rhematoid arthritis, slows the progression of damage to the joints, and improves the physical function of patients
![Page 20: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/20.jpg)
• Adverse Effects– Increased risk of upper respiratory tract– concomitant use with TNF antagonists is NOT
recommended due to increased risk of infection
Source: Basic and Clinical Pharmacology 10th edition, 2007 by Katzung
![Page 21: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/21.jpg)
IMMUNOSUPPRESSIVE THERAPY
5th line of therapy
![Page 22: NSAIDs 1 st line of therapy in the medical management of RA](https://reader036.vdocuments.site/reader036/viewer/2022070307/551b461c550346d31b8b4a1a/html5/thumbnails/22.jpg)
• Azathioprine, leflunomide, cyclosporine and cyclophosphamide
• Effective in the treatment of RA and exerts therapeutic effects similar to DMARDs
• DMARDs > immunosuppressive agents• Increase toxicities• Reserved for patients who have failed DMARDs
and biologics therapy
Source: Harrison’s Principles of Internal Medicine 17th ed.